Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cystamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.91 |
| ▸ | THPO | P40225 | 1/20 | 0.91 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cystamine SCHEMBL196510 | 1.00 | — | — | |
| Cystamine SCHEMBL28842776 | 1.00 | MAPT (1.00) | MAPTTDP1EHMT2TSHRTHPO | |
| Cystamine SCHEMBL28235943 | 1.00 | MAPT (1.00) | MAPTTDP1EHMT2TSHRTHPO | |
| Cystamine SCHEMBL320311 | 1.00 | MAPT (1.00) | MAPTTDP1EHMT2TSHRTHPO | |
| Cystamine SCHEMBL28418529 | 0.96 | MAPT (0.92) | MAPTTDP1EHMT2TSHRTHPO | |
| Cystamine SCHEMBL7903150 | 0.96 | MAPT (0.92) | MAPTTDP1EHMT2TSHRTHPO | |
| Cystamine SCHEMBL28409923 | 0.96 | MAPT (0.92) | MAPTTDP1EHMT2TSHRTHPO | |
| Cystamine SCHEMBL43866 | 0.95 | — | — | |
| Cystamine SCHEMBL3648870 | 0.95 | TSHR (1.00) | MAPTTDP1EHMT2TSHRTHPO | |
| Cystamine SCHEMBL11040994 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112294776-B | Reduction response type carbon dot drug-loaded nanocluster coated with cell membrane and preparation and application thereof | 东华大学 | 2021-08-31 | — | — | CN | claimed |
| CN-112294776-A | Reduction response type carbon dot drug-loaded nanocluster coated with cell membrane and preparation and application thereof | 东华大学 | 2021-02-02 | — | — | CN | claimed |
| CN-109069656-B | Oral nanoparticles for gene delivery and pharmaceutical compositions comprising the same | KB生物医药株式会社 | 2022-09-09 | — | — | CN | disclosed |
| EP-2285772-B1 | NEW CLASS OF CATIONIC LIPIDS FOR TRANSPORTING ACTIVE AGENTS INTO CELLS | OZ BIOSCIENCES SAS (FR) | 2022-07-13 | — | — | EP | disclosed |
| US-11266747-B2 | Orally administered nanoparticles for gene delivery and pharmaceutical composition containing same | KB BIOMED INC. (KR) | 2022-03-08 | — | — | US | disclosed |
| CN-112294776-B | Reduction response type carbon dot drug-loaded nanocluster coated with cell membrane and preparation and application thereof | 东华大学 | 2021-08-31 | — | — | CN | disclosed |
| CN-112294776-A | Reduction response type carbon dot drug-loaded nanocluster coated with cell membrane and preparation and application thereof | 东华大学 | 2021-02-02 | — | — | CN | disclosed |
| US-20190111156-A1 | Orally Administered Nanoparticles for Gene Delivery and Pharmaceutical Composition Containing Same | KB BIOMED INC. (KR) | 2019-04-18 | — | — | US | disclosed |
| CN-109069656-A | Oral nanoparticles for gene delivery and pharmaceutical compositions comprising the same | KB生物医药株式会社 | 2018-12-21 | — | — | CN | disclosed |
| EP-3017307-B1 | 3-ARYL PROPIOLONITRILE COMPOUNDS FOR THIOL LABELING | UNIV STRASBOURG (FR) | 2018-11-21 | — | — | EP | disclosed |
| US-10131626-B2 | 3-aryl propiolonitrile compounds for thiol labeling | UNIVERSITE DE STRASBOURG (FR) | 2018-11-20 | — | — | US | disclosed |
| US-6982324-B1 | Degradable macromolecular magnetic resonance imaging contrast agents and methods thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2006-01-03 | — | — | US | disclosed |
| EP-0650485-B1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED INC (US) | 2000-10-11 | — | — | EP | disclosed |
| US-5856323-A | PAF RECEPTOR ANTAGONISTS, INHIBITING THE ENZYME 5-LIPOXYGENASE | CYTOMED, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5434151-A | Treatment of immune and inflammatory disorders, aryl substituted tetrahydrofurans, tetrahydrothiophenes, cyclopentanes, pyrrolidines | CYTOMED, INC. (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0650485-A1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1995-05-03 | — | — | EP | disclosed |
| US-5358938-A | 2,5-Diaryl tetrahydrofurans, tetrahydrothiophenes, 1,3-cyclo-pentanes and pyrrolidines | CYTOMED, INC. (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994001430-A1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1994-01-20 | — | — | WO | disclosed |
| US-4837316-A | ANTIULCER AGENTS | FUJIREBIO KABUSHIKI KAISHA (JP) | 1989-06-06 | — | — | US | disclosed |
| EP-0214823-A2 | Alkylamide derivatives with H2-receptor antagonistic and cytoprotective action | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10131626-B2 | 3-aryl propiolonitrile compounds for thiol labeling | PTMS, TST, PNN | MAPT 885/4885TDP1 3594/4885EHMT2 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.